Project Grant R61NS138063
Award Date
8/15/24
Completion Date
7/31/27
Dollars Obligated
$1.7M
Funding Federal Agency
National Institute on Aging
Awarding Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This National Institute on Aging (NIA) Project Grant award (CFDA 93.866 - Aging Research) provides $237,160 to Northwestern University to investigate the role of striatal astrocytic dopamine D2 receptor signaling in the pathogenesis of LRRK2-mediated Parkinson's disease. The project aims to mechanistically link impaired D2 receptor signaling and inflammation in striatal astrocytes expressing the LRRK2G2019S mutation, a common genetic cause of familial Parkinson's disease. The research will...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to Case Western Reserve University (CWRU) provides $2,069,215 to investigate the role of the beta-arrestin2-LMBRD2 cascade in the pathogenesis of alpha-synuclein aggregation, a hallmark of Lewy body diseases such as Parkinson's disease and dementia with Lewy bodies. The award will support cellular and animal model studies to elucidate the mechanisms by which the binding of beta-arrestin2 to...
This $227,205 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the effects of the Parkinson's disease-associated protein LRRK2 on lysosomal function and inflammatory activity in microglia. The primary objectives are to: 1) examine how LRRK2 and the Parkinson's disease risk gene GBA1 interact to regulate lysosomal...
This $603,031 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Northwestern University supports a 1-year research study on the clinical, cellular, and pathological features of comorbid Alzheimer's disease and TDP-43 proteinopathies in elderly patients with amnestic dementia. The key objectives are to: 1) identify the shared versus distinct clinical, neuropsychological, and psychiatric characteristics of this condition; 2) determine the cellular...
This $1,510,600.00 federal Project Grant award, provided by the National Institute on Aging under CFDA Program 93.866 Aging Research, will fund a research study to map synaptic density changes in the brains of individuals with Lewy body dementia, from the prodromal to manifest stages of the disease. The project, led by the University of Wisconsin-Madison, will recruit 160 participants, including those with rapid eye movement sleep behavior disorder, early-stage Parkinsonism, and mild cognitive...
This three-year, $4.766 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, aims to clarify the neuropathological, molecular, and genetic differences between Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) through the Aging Research grant program (CFDA 93.866). The J. David Gladstone Institutes will use digital pathology, artificial intelligence, single-nuclei RNA sequencing, and spatial transcriptomics on...
This Project Grant award for $655,638 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to develop synthetic protein mimetics as potential therapeutics for Lewy body dementia (LBD). The University of Denver will optimize and test the pharmaceutical properties of these oligopyridylamide (OP) compounds, which have demonstrated the ability to inhibit alpha-synuclein aggregation and Lewy body formation in cellular and animal models. The research will also...
The National Institute on Aging (NIA) awarded a $716,000 Project Grant (CFDA 93.866 - Aging Research) to Brigham & Women's Hospital Inc. in Boston, MA. The grant, titled "Distinguishing A-Synuclein S129 Phosphorylation in Health and Lewy Body Dementia," aims to compare the biochemical properties of physiological and pathological phosphorylation of the A-synuclein protein and describe the impact on synaptic transmission in Parkinson's disease and Lewy body dementia models. The...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $7,704,350 to The Trustees of the University of Pennsylvania to conduct research on the "Mechanisms Underlying Heterogeneity of Cognitive Outcomes in Synucleinopathy." The five-year project, running from September 2024 to August 2029, aims to understand why the same underlying pathology (alpha-synuclein inclusions) can lead to dramatically different cognitive outcomes in Lewy body...
This $682,493 federal Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to elucidate the role of aberrant histone acetylation in the pathogenesis of Parkinson's disease, Lewy body dementia, and related synucleinopathies. The research team at Albert Einstein College of Medicine in Bronx, NY is employing human pluripotent stem...